Curium sets Bexlutry price below Novartis' Lutathera
Curium has set a list price of $63,524 per infusion for Bexlutry, a generic radioligand comparable to Novartis' Lutathera. The price is about 5% lower than Lutathera's. The move sets up competition in the radiopharmaceutical sector.
Curium has set a list price of $63,524 per infusion for Bexlutry. Bexlutry is a generic radioligand comparable to Novartis’ Lutathera. Its list price is about 5% lower than Lutathera’s.
The move sets up competition in the radiopharmaceutical sector, with two comparable radioligand therapies now linked by a pricing comparison. The available details focus on the list price difference and the competitive positioning between Curium’s product and Novartis’ treatment.
The lower list price for Bexlutry may give patients and clinicians another comparable radioligand option, potentially influencing treatment discussions if coverage and access follow. Payers could see modest price pressure in this niche, though a 5% list-price difference may have limited budget impact. Competitors may respond with their own pricing or contracting strategies. Overall, the effect on society likely depends on real-world access, reimbursement, and clinical uptake, not list price alone.